GlassScriptPhysician profile
John C Finn
NPI 1801869722
$1,066.54
in general payments reported to CMS, 2019-2025
8 companies · $85.20 in 2025
The $85.20 reported for 2025 was less than what a typical Plastic Surgery Within The Head and Neck provider received nationally (typical 2025 total: $300).
See the full distribution for Plastic Surgery Within the Head and Neck
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $27.88 · 2021: $156 · 2022: $175 · 2023: $174 · 2024: $135 · 2025: $85.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $453.25 | 2019-2022 | |
| Galderma Laboratories, L.P. | $346.09 | 2019-2025 | |
| Revance Therapeutics, INC. | $94.01 | 2024-2025 | Daxxify |
| Abbvie INC. | $67.48 | 2023 | |
| Aclaris Therapeutics, INC. | $52.83 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.50 | 2019 | |
| Integra Lifesciences Corporation | $15.44 | 2025 | Integra, Surgimend, Omnigraft |
| Merz North America, INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Finn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.